This company is no longer active
ANGN Stock Overview
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Angion Biomedica Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.00 |
| 52 Week High | US$2.04 |
| 52 Week Low | US$0.46 |
| Beta | 0.60 |
| 1 Month Change | 48.92% |
| 3 Month Change | 50.24% |
| 1 Year Change | -37.89% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.12% |
Recent News & Updates
Recent updates
Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky
Apr 27
Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely
Jan 05We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully
Sep 11Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M
Aug 15Angion to discontinue phase 2 trial of ANG-3070 in patients with kidney disease
Jun 29We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth
Mar 19Angion Biomedica: Selling At Cash Value
Feb 07Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price
Oct 05We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely
Aug 18Shareholder Returns
| ANGN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 17.7% | -2.3% | -3.7% |
| 1Y | -37.9% | 11.4% | 20.2% |
Return vs Industry: ANGN underperformed the US Pharmaceuticals industry which returned -1.4% over the past year.
Return vs Market: ANGN underperformed the US Market which returned -1% over the past year.
Price Volatility
| ANGN volatility | |
|---|---|
| ANGN Average Weekly Movement | 14.9% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANGN's share price has been volatile over the past 3 months.
Volatility Over Time: ANGN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 8 | Jay Venkatesan | www.angion.com |
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid.
Angion Biomedica Corp. Fundamentals Summary
| ANGN fundamental statistics | |
|---|---|
| Market cap | US$30.11m |
| Earnings (TTM) | -US$29.10m |
| Revenue (TTM) | US$653.00k |
46.1x
P/S Ratio-1.0x
P/E RatioIs ANGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANGN income statement (TTM) | |
|---|---|
| Revenue | US$653.00k |
| Cost of Revenue | US$6.76m |
| Gross Profit | -US$6.11m |
| Other Expenses | US$23.00m |
| Earnings | -US$29.10m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | -935.07% |
| Net Profit Margin | -4,456.97% |
| Debt/Equity Ratio | 0% |
How did ANGN perform over the long term?
See historical performance and comparison